Zhao Xiaofei, Zhang Cairong, Liu Xiaojuan, Ma Zhenghai
College of Life Science and Technology, Xinjiang University, Urumqi 830046, China.
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2014 Nov;30(11):1142-5.
To analyze the humoral immune response induced by recombinant Lactococcus lactis expressing HIV-1 gag in mice immunized orally, intranasally, subcutaneously or in the combined way of above three.
Fifty BALB/c mice were randomly divided into 5 groups, 10 mice per group. The mice were immunized consecutively three times at two week intervals with 10(9) CFU of recombinant Lactococcus lactis expressing gag through oral, intranasal, subcutaneous administration or the mix of them. The mice that were immunized orally with Lactococcus lactis containing PMG36e served as a control group. The sera of mice were collected before primary immunization and 2 weeks after each immunization to detect the gag specific IgG by ELISA.
Compared with the control group, the higher titer of serum gag specific IgG was detected in the four groups immunized with recombinant Lactococcus lactis expressing gag, and it was the highest in the mixed immunization group (P<0.01). The titer of serum gag specific IgG from the oral and subcutaneous immunization groups was significantly higher than that from the intranasal immunization group (P<0.01) 6 weeks after primary immunization . The serum antibody positive rates of the oral immunization group after the first, the second, the third immunization were 40%, 40%, 90%, respectively; the positive rates of the intranasal immunization group were 10%, 20%, 20%; the positive rates of the subcutaneous immunization group were 10%, 60%, 90%; the positive rate of the combined immunization group reached 100% 2 weeks after primary immunization.
Recombinant Lactococcus lactis expressing gag can induce humoral immune response in mice by oral, intranasal, subcutaneous injection or the mix of them, and the mixed immunization can enhance the immune effects of Lactococcus lactis vector vaccine.
分析表达HIV-1 gag的重组乳酸乳球菌经口服、鼻内、皮下或以上三种方式联合免疫小鼠后诱导的体液免疫反应。
将50只BALB/c小鼠随机分为5组，每组10只。每隔两周用10⁹CFU表达gag的重组乳酸乳球菌通过口服、鼻内、皮下给药或联合给药方式连续免疫小鼠3次。用含PMG36e的乳酸乳球菌经口服免疫的小鼠作为对照组。在初次免疫前及每次免疫后2周收集小鼠血清，用ELISA法检测gag特异性IgG。
与对照组相比，用表达gag的重组乳酸乳球菌免疫的4组小鼠血清gag特异性IgG滴度较高，其中联合免疫组最高（P<0.01）。初次免疫6周后，口服和皮下免疫组血清gag特异性IgG滴度显著高于鼻内免疫组（P<0.01）。口服免疫组第一次、第二次、第三次免疫后的血清抗体阳性率分别为40%、40%、90%；鼻内免疫组分别为10%、20%、20%；皮下免疫组分别为10%、60%、90%；联合免疫组在初次免疫2周后阳性率达100%。
表达gag的重组乳酸乳球菌可通过口服、鼻内、皮下注射或联合方式诱导小鼠产生体液免疫反应，联合免疫可增强乳酸乳球菌载体疫苗的免疫效果。
